Table 1. Comparison of ADC components with time for whole prostate and tumour regions over the entire cohort and in the subsets of those who progressed to radical treatment and those who did not.

	ADCall		ADCfast		ADCslow
	WP mean±SD × 10−3	*Tumour mean±SD × 10−3	WP mean±SD × 10−3	*Tumour mean±SD × 10−3	WP mean±SD × 10−3	*Tumour mean±SD × 10−3
Whole group TP1	1.73±0.14	1.43±0.29	1.99±0.16	1.62±0.32	1.35±0.10	1.16±0.24
Whole group TP2	1.74±0.10	1.34±0. 24	1.94±0.11	1.52±0.26	1.35±0.10	1.11±0.21
p-value (TP1 vs TP2)	0.35	0.06	0.11	0.049	0.72	0.3
Progressors TP1	1.76±0.10	1.33±0.20	2.03±113	1.53±0.23	1.37±0.09	1.08±0.18
Progressors TP2	1.684±0.08	1.20±0.13	1.92±0.09	1.37±0.17	1.33±0.08	1.00±0.12
p-value (TP1 vs TP2)	0.02	0.03	0.007	0.03	0.18	0.16
Non-progressors TP1	1.72±0.16	1.49±0.33	1.97±0.18	1.68±0.36	1.34±0.10	1.21±0.25
Non-progressors TP2	1.72±0.12	1.41±0.26	1.96±0.12	1.60±0.26	1.37±0.11	1.17±0.23
p-value (TP1 vs TP2)	0.92	0.36	0.72	0.37	0.23	0.54

*Tumour values for n = 26 non-progressors and n = 16 progressors in whom a tumour was visible. Whole prostate (WP) values are given for the entire cohort. TP, time-point. ADC, apparent diffusion coefficient.